MYOCD and sarcoma: MYOCD depletion in an LMS cell line reduced smooth muscle differentiation and migration, and overexpression of MYOCD in undifferentiated sarcoma cell lines increased smooth muscle differentiation and migration, suggesting MYOCD as a potential therapeutic target in LMS [152], particularly well-differentiated LMS.